Cargando…

Estimation of anti-SARS-CoV-2 IgG titre among blood donors in Ranchi

INTRODUCTION: Coronavirus disease 2019 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as novel coronavirus (2019-nCoV). The disease presentation ranges from asymptomatic to severe acute respiratory failure requiring intensive care support. Anti-SARS-CoV-2 IgG a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumari, Sushma, Saroj, Usha, Verma, Ashwini, Kumar, Abhay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810935/ https://www.ncbi.nlm.nih.gov/pubmed/36618231 http://dx.doi.org/10.4103/jfmpc.jfmpc_727_22

Ejemplares similares

A cross-sectional study of clinical and laboratory characteristics of systemic lupus erythematosus in tribal region of Jharkhand at RIMS, Ranchi
por: Kumar, Ravi, et al.
Publicado: (2022)

Serum MOG IgG titres should be performed routinely in the diagnosis and follow-up of MOGAD: Yes
por: Reindl, Markus, et al.
Publicado: (2023)

Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors
por: Uyoga, Sophie, et al.
Publicado: (2021)

SARS-CoV-2 IgG Surveillance in Asymptomatic Blood Donors and Health Workers
por: Chandra, Tulika, et al.
Publicado: (2021)

Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-2 IgG
por: Sapkal, Gajanan, et al.
Publicado: (2020)

Effect of recurrent invasive pneumococcal disease on serum anti-pneumolysin IgG titres in HIV infected adults
por: Etuwewe, Onajite M., et al.
Publicado: (2009)

SARS-CoV-2 spike IgG titres up to 137 days following Comirnaty mRNA COVID-19 vaccination, Israel, February to May 2021
por: Patalon, Tal, et al.
Publicado: (2022)

Estimation of SARS-CoV-2 IgG Antibodies in Healthcare Worker-Administered Covishield and Covaxin Vaccines at a Tertiary Care Hospital in Jharkhand, India
por: Singh, Bishnupati, et al.
Publicado: (2023)

Combined Analysis of Anti SARS-CoV-2 IgG and IgM Responses in COVID19 Patients in India
por: Chidananda, Mohana Kumari, et al.
Publicado: (2021)

Risk factors for relapse in pediatric nephrotic syndrome in Ranchi
por: Mishra, Rajeeva, et al.
Publicado: (2023)

SARS-COV-2 IgG and IgM Antibodies in Cancer Patients
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

The seroprevalence of SARS-CoV-2 IgG antibodies among asymptomatic blood donors in Saudi Arabia
por: Mahallawi, Waleed H., et al.
Publicado: (2021)

SARS COV-2- IgG antibodies in blood donors in pandemic – A game changer for policy makers
por: Mahapatra, S.
Publicado: (2022)

IgG antibodies to SARS-CoV-2 in asymptomatic blood donors at two time points in Karachi
por: Hasan, Muhammad, et al.
Publicado: (2022)

Persistence of IgG response to SARS-CoV-2
por: Duysburgh, Els, et al.
Publicado: (2021)

SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study
por: Spinelli, Matthew A, et al.
Publicado: (2021)

Correction to: Combined Analysis of Anti SARS-CoV-2 IgG and IgM Responses in COVID19 Patients in India
por: Chidananda, Mohana Kumari, et al.
Publicado: (2021)

Subclasses of allergen-specific IgG: Serum IgG2 and IgG3 levels are not predicted by IgG1/IgG4 levels
por: MacGlashan, Donald, et al.
Publicado: (2021)

SARS-CoV-2 IgG and IgA antibody response is gender dependent; and IgG antibodies rapidly decline early on
por: Korte, Wolfgang, et al.
Publicado: (2021)

SARS-CoV-2 IgG Antibody and its Clinical Correlates in Convalescent Plasma Donors: An Indian Experience
por: Kumar, PVSN Kiran, et al.
Publicado: (2021)

418. Comparison of the Abbott SARS-CoV-2 IgG and DiaSorin LIASON SARS-CoV-2 S1/S2 IgG Antibody Assays
por: Schaack, Grace A, et al.
Publicado: (2020)

Evaluation of Abbott anti-SARS-CoV-2 CMIA IgG and Euroimmun ELISA IgG/IgA assays in a clinical lab
por: Manalac, Justin, et al.
Publicado: (2020)

Comparaison des tests sérologiques SARS-CoV2 Euroimmun IgG, Abbott IgG et Wantai Ac totaux
por: Petillon, C., et al.
Publicado: (2020)

IgG response to spike protein of SARS-CoV-2 in healthy individuals and potential of intravenous IgG as treatment for COVID-19
por: Wang, Gang, et al.
Publicado: (2022)

The antiinflammatory activity of IgG: the intravenous IgG paradox
por: Nimmerjahn, Falk, et al.
Publicado: (2007)

Cross-sectional IgM and IgG profiles in SARS-CoV-2 infection
por: Ozturk, Tugba, et al.
Publicado: (2020)

Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine
por: Banga Ndzouboukou, Jo-Lewis, et al.
Publicado: (2021)

IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein
por: Lopandić, Zorana, et al.
Publicado: (2021)

Seroprevalence of IgG Anti-SARS-CoV-2 among Voluntary Blood Donors in Dubai: Demographic and Risk Factors
por: Raouf, May, et al.
Publicado: (2021)

Seroprevalence of SARS-CoV-2 IgG antibody among healthy blood donors: a single centre study
por: Jaiswal, Ram, et al.
Publicado: (2022)

SARS-CoV-2 IgG Seroprevalence among Blood Donors as a Monitor of the COVID-19 Epidemic, Brazil
por: Chaves, Daniel Gonçalves, et al.
Publicado: (2022)

SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021
por: Gallian, Pierre, et al.
Publicado: (2023)

SARS-CoV-2 IgG Levels Allow Predicting the Optimal Time Span of Convalescent Plasma Donor Suitability
por: Laner-Plamberger, Sandra, et al.
Publicado: (2022)

Impact of the COVID-19 Pandemic on Blood Donation Patterns: A Systematic Review and Meta-Analysis
por: Kumar, Abhay, et al.
Publicado: (2023)

Serum IgG4 levels outperform IgG4/IgG RNA ratio in differential diagnosis of IgG4-related disease
por: Schulte, Lucas A., et al.
Publicado: (2020)

Activation of SARS-CoV-2 neutralizing antibody is slower than elevation of spike-specific IgG, IgM, and nucleocapsid-specific IgG antibodies
por: Takahashi, Maika, et al.
Publicado: (2022)

Comparative evaluation of SARS-CoV-2 IgG assays in India()
por: Chaudhuri, Susmita, et al.
Publicado: (2020)

SARS-COV-2 IgG antibody response in pregnant women at delivery
por: Tsatsaris, Vassilis, et al.
Publicado: (2021)

Long-Term Persistence of Anti-SARS-COV-2 IgG Antibodies
por: Yousefi, Zahra, et al.
Publicado: (2022)

Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders
por: Marklund, Emelie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kn5t7jhskt863sn7nrc4krsdeq